Amicus Therapeutics, Inc.
General ticker "FOLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.4B (TTM average)
Amicus Therapeutics, Inc. follows the US Stock Market performance with the rate: 43.1%.
Estimated limits based on current volatility of 0.0%: low 14.45$, high 14.46$
Factors to consider:
- Total employees count: 499 as of 2024
- US accounted for 33.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Third-party risks, Regulatory and compliance, Market acceptance, Market competition, Intellectual property risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.60$, 17.84$]
- 2026-12-31 to 2027-12-31 estimated range: [10.24$, 18.70$]
Financial Metrics affecting the FOLD estimates:
- Positive: with PPE of 61.7 at the end of fiscal year the price was low
- Positive: -4.72 < Operating profit margin, % of 5.44
- Positive: 19.49 < Shareholder equity ratio, % of 28.87 <= 42.60
- Positive: 0.07 < Operating cash flow per share per price, % of 0.79
- Negative: Inventory ratio change, % of 8.16 > 0.80
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Negative: 0.73 < Interest expense per share per price, % of 1.10
- Positive: -4.45 < Investing cash flow per share per price, % of -1.11
- Negative: negative Industry operating income (median)
Short-term FOLD quotes
Long-term FOLD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $396.77MM | $528.29MM | $634.21MM |
| Operating Expenses | $473.98MM | $503.42MM | $599.72MM |
| Operating Income | $-77.21MM | $24.88MM | $34.49MM |
| Non-Operating Income | $-72.89MM | $-53.63MM | $-34.30MM |
| Interest Expense | $50.15MM | $49.60MM | $46.16MM |
| R&D Expense | $152.38MM | $109.36MM | $135.84MM |
| Income(Loss) | $-150.10MM | $-28.76MM | $0.19MM |
| Taxes | $1.48MM | $27.35MM | $27.30MM |
| Profit(Loss)* | $-151.58MM | $-56.11MM | $-27.11MM |
| Stockholders Equity | $160.17MM | $194.04MM | $274.24MM |
| Inventory | $59.70MM | $118.78MM | $228.82MM |
| Assets | $777.88MM | $785.03MM | $949.87MM |
| Operating Cash Flow | $-69.09MM | $-33.89MM | $33.15MM |
| Capital expenditure | $7.44MM | $3.55MM | $3.30MM |
| Investing Cash Flow | $98.06MM | $-0.56MM | $-46.43MM |
| Financing Cash Flow | $61.68MM | $5.12MM | $0.61MM |
| Earnings Per Share** | $-0.51 | $-0.18 | $-0.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.